Paion AG (FRA:PA8K)

Market Cap	884.58K +545.8%
Revenue (ttm)	14.81M -48.5%
Net Income	-19.86M
EPS	-2.79
Shares Out	7.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,920
Average Volume	8,922
Open	0.0830
Previous Close	0.0930
Day's Range	0.0830 - 0.1240
52-Week Range	0.0002 - 0.2300
Beta	4.14
RSI	56.24
Earnings Date	Aug 29, 2025

About Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distribu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 64
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PA8K

Financial Performance

In 2022, Paion AG's revenue was 33.25 million, an increase of 366.44% compared to the previous year's 7.13 million. Losses were -579,000, -97.34% less than in 2021.